Melphalan

Meantime a few colleagues check the breast tissue to see if there is a malignant change. Cancerous cells are not stacked as orderly as healthy tissue, but their blood supply is better and thus it is easier for us to reach them. That's how we light up the tumor. Since malignant cells proliferate indiscriminately, we cannot run off as easily here as in healthy tissue. Central command immediately notices something like that. As you can see, I have a highly demanding and arduous job probably one of the most difficult professions in my sector. But even a top agent like me cannot manage everything or be everywhere he is needed at the same time. This is why we also have special agents called blood pool agents with the code name MS-325. They check, for example, whether the traffic flows smoothly in all blood vessels. These traffic controllers are also gadolinium chelates like we are, but they use a different tactic. They immediately hop on to large protein clusters albumins ; , where their influence on the informants is increased, and comfortably ride on them throughout the blood vessel system. They remain 10 times longer in the blood vessels than we extracellular agents do, because when they ride piggyback on proteins they are much too fat to slip into surrounding tissue. But that is not their job anyway. Their assignment is to track down spots where the enemy has committed acts of sabotage, such as clogged arteries and obstructed blood vessels. This work tires them so much that slowly but surely they lose their grip, slip from the albumin and land completely exhausted in the kidneys, where eventually everyone meets. I personally prefer the P agents. These really crafty guys patrol the liver. Carrier proteins unload diseased and used cells here in the body's central waste disposal plant. Unfortunately, straggler tumor cells from the in.

Melphalan therapy Aim was to slow the ventricular rates, not to convert atrial fibrillation to regular sinus rhythm. All patients were given potassium chloride through a central venous catheter the day of operation, and subsequently, they were given oral potassium chloride, 16 mEq twice a day in addition to. What is Melphalan Presumed risk of prolonged leukopenia and severe myelotoxicity. We demonstrated with our analysis that chemotherapy is feasible in patients on haemodialysis without unpredictable severe side effects. The task is to find dose adjustment models for cytotoxic drugs and to modify existing chemotherapy protocols adequately for patients receiving haemodialysis. Blood concentration monitoring and target range-based methotrexate dose adjustment according to individual renal function and drug clearance can significantly improve survival outcome, as has been shown in childhood leukaemia [12]. The administered dosages were found to be significantly higher than the proposed adjustments according to Dettli's proportional dose reduction rule. We have supplemented the dose calculated by Dettli's rule to replace the drug elimination by haemodialysis. The effect of haemodialysis on carboplatin kinetics is found to be considerable, but not on etoposide kinetics [13]. We even increased the initial doses in two cycles. Overall, in 28 cytotoxic drug cycles, the administered dosage was significant higher 119% ; than that suggested by Dettli's rule P 0.01 ; . Also for antimicrobial drugs, dose proposals based on Dettli's rule were also found to be too low in patients with renal impairment [14]. The Giusti and Hayton model is based only on the renally eliminated fraction of the unchanged drug as determined in patients with normal renal function. With the Dettli rule, in contrast, the clearance or halflife values can be used as determined in a renal failure patient population. Dettli's rule is helpful in the prevention of severe haematotoxic effects of cytotoxic drugs with a total renal elimination of 30%. We administered cisplatin to one patient with a small dose reduction to still 80% of the regular dose, in contrast to 53% calculated by Dettli's rule. In patients with lung cancer, blood concentration monitoring was performed, and the fraction of free cisplatin and total cisplatin removed by haemodialysis was calculated as 8722 and 4412%, respectively [5]. Haemodialysis in this trial was performed immediately after the administration of cisplatin. In contrast, our patient received cisplatin chemotherapy after dialysis. Patients on haemodialysis have a significantly higher mortality risk due to sepsis [4]. Three of our patients with haemoblastic malignancies and high dose chemotherapy died from infection. Overall, the progression of the malignancy was the main lethal event in our patients, and progression was associated with a Karnofsky index below 40% in six patients. The median survival of our patients with multiple myeloma was 30 months. The survival of patients with multiple myeloma and renal failure is reported as 2 months without chemotherapy, 10 months with vincristine, adriamycin and dexamethasone therapy, and 12 months with melphalan protocols [15]. Successful autologous stem cell transplantation has been performed recently with higher dose melphalan in haemodialysis patients [16, 17]. Melphalan is the most frequently used drug in this phase of treatment.

Prescription Drugs Isolation of CDDP-resistant Variants of CHO Cells and Cell Culture. CHO cells were grown in monolayer in minimal essential medium Nissui Seiyaku Co., Tokyo, Japan ; containing 10% newborn calf serum Microbiological Associates, Bethesda, MD ; , l mg ml Bacto-peptone Difco Laboratories, Detroit, MI ; , L-glutaminc 0.292 mg ml ; , kanamycin 100 Mg ml ; . and penicillin 100 units ml ; 5, 6 ; . CDDP-resistant variants of CHO cells were isolated by stepwise selection on exposure to increasing doses of CDDP. CHO cells were exponentially grown at 106 100-mm dish, and CDDP was then added to the medium for 3-week intervals at increasing concentrations of 0.2, 0.5. 1.0, and 4.0 Mg ml CDDP. During the continuous expo sure to CDDP, culture medium was replaced with freshly prepared medium containing CDDP at indicated concentrations every 4-5 days. Colonies selected at each step when exposed to 1.5 and 4.0 Mg ml CDDP were purified, and each purified clone was named C CDP-1 and C CDP-2, respectively. CDDP-sensitive revenants were isolated from CDP-1 after continuous incubation of C CDP-2 for 5 months in the absence of CDDP, and a purified revenant was named R-l. We have also isolated a CDDP-resistant cell line, P CDP-5, from a human prostate cancer PC-3 cell line following the same selection method as that for C CDP-1 or C CDP-2. Chemicals. CDDP and VP-16 were obtained from Ninon Kayaku Company, Tokyo, Japan; carboplatin and teniposide were from Bristol Meyer Co., Kanagawa, Japan; Adriamycin and CdSO4 were from Sigma Chemical Co., St. Louis, MO; mitomycin C and melphalan were from Kyowa Hakko Co., Tokyo, Japan. l-Chloro-2, 4-dinitrochlorobenzene was purchased from Nakarai Chemicals, Ltd., Kyoto, Japan. [IJC]Thymidine 53.2 mCi mmol ; and ['Hjthymidine 20 Ci mmol ; were purchased from New England Nuclear, Boston, MA. Colony Formation and Growth Curves. To assay colony formation, we first seeded 300 cells of CHO, R-l, and 3000 cells of C CDP-I, C CDP-2, and P CDP-5 in a 35-mm dish in the absence of drugs at 37'C for 18 h. Cells were incubated for an additional 7 days with various drugs. Colonies appeared with a plating efficiency of 70-80% CHO, R-l, and PC-3 ; and 7-8% C CDP-1. C CDP-2, and P CDP-5 ; . Col ony number was counted after Giemsa staining 6. 7 ; . Drugs were freshly prepared in dimethyl sulfoxide or ethanol and all control exper iments were done by adding the same amount of the solvent. To calculate relative resistance to various anticancer agents, the dose required to reduce the surviving fraction to 10% of the initial fraction LDW ; of each cell line was compared with that of each parental cell line. To assay growth curves. IO4cells were plated and the next day the cells were exposed to 0, 1.5, or 3.0 Mg ml of CDDP for an additional 4 days. Medium was changed with freshly prepared CDDP every 2 days and the number of surviving cells was counted by trypan dye exclusion. Alkaline Elution Assay. The alkaline elution procedure was done according to the published method 8, 9 ; . Cells 3 x IO6 ; were seeded in 35-mm dishes and incubated at 37'C for 24 h in minimal essential medium containing 0.02 iCi [l4C]thymidine. The sample cells exposed to [MC]thymidine were then exposed to various concentrations of CDDP for 2 h and irradiated on ice prior to elution. Control cells which were not treated with CDDP were incubated with 0.2 MCi|'H]. Plasma melphalan levels are highly variable after oral dosing, both with respect to the time of the first appearance of melphalan in plasma range approximately 0 to 6 hours ; and to the peak plasma concentration c max ; range 70 to 4, 000 ng ml, depending upon the dose ; achieved and memantine. 16. Bjorkstrand B, Svensson H, Goldschmidt H et al. 5489 autotransplants in multiple myeloma: A registry from the EBMT. Blood 1999; 94 Suppl 1 ; , 714 a Abstr ; . 17. Moreau P, Milpied N, Mah B. Melphalan 220 mg m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23: 10001006. Moreau P, Harousseau JL, Wijdenes J et al. A combination of antiinterleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rate in advanced multiple myeloma. Br J Haematol 2000; 109: 661664. Harousseau JL, Milpied N, Laporte JP et al. Double intensive therapy in high-risk multiple myeloma. Blood 1992; 79: 28272833. Vesole D, Barlogie B, Jagannath S et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950956. Weaver CH, Zhen B, Schwartzberg LS et al. Phase III evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Bone Marrow Transplant 1998; 22: 245251. Bjorkstrand B, Ljungman P, Bird JM et al. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remission in multiple myeloma. Bone Marrow Transplant 1995; 15: 367371. Vesole D, Tricot G, Jagannath S et al. Autotransplant in multiple myeloma: what have we learned? Blood 1996; 88: 838847. Desikan R, Barlogie B, Sawyer J et al. Results of high dose therapy for 1000 patients with multiple myeloma: durable complete remission and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 40084010. Attal M, Harousseau JL, Facon T et al. Single versus double transplant in myeloma: a randomized trial of the IFM. Proc VIIIth Int Myeloma Workshop 2001: S15; 28 Abstr ; . 26. Segeren CM, Sonneveld P, Van Der Holt P et al. Myeloablative treatment in following intensified chemotherapy untreated multiple myeloma: a prospective randomized phase III study. Blood 2001; 98: 815a. Cavo M, Tosi P, Zamagni E et al. The Bologna 96 clinical trial of single versus double PBSC transplantation for previously untreated MM: results of an interim analysis. Proc VIIIth Int Myeloma Workshop 2001; S16: 2930. 28. Fermand JP, Marolleau JP, Alberti C et al. Single versus tandem high dose therapy supported with autologous stem cell transplantation using unselected or CD 34 enriched ABSC: preliminary results of a two by two designed randomized trial in 23 young patients with multiple myeloma. Blood 2001; 98: 815a Abstr ; . 29. Schiller G, Vescio R, Freytes C et al. Transplantation of CD 34 peripheral blood progenitor cell after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390397. Lemoli RM, Fortuna A, Motta MR et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD 34 + cells to remove circulating tumor cells. Blood 1996; 87: 16251634. Vescio RA, Schiller G, Stewart K et al. Multicenter phase III trial to evaluate CD 34 + selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999; 93: 18581868. Stewart AK, Vescio K, Schiller G et al. Purging of autologous peripheral blood stem cells using CD34 selection does not improve.

Maxitrol Neomycin; Polymyxin B and Dexamethasone ; Measles Mumps Rubella Varicella Vaccine Live Proquad ; Measles, Mumps, and Rubella Virus Vaccine Live MMR Ii ; Mebendazole Vermox ; Mecasermin [rDNA origin] Inj Increlex ; Mechlorethamine HCl Mustargen ; Meclofenamate Meclofenamate ; Medroxyprogesterone Depo Provera ; Medroxyprogesterone Acetate Provera ; Mefenamic Acid Ponstel ; Mefoxin Cefoxitin ; Megace ES Megestrol Acetate ; Megestrol Acetate Megace ES ; Meloxicam Mobic ; Melphalan Hcl Inj Alkeran Inj ; Menactra Polysaccharide Diphtheria Toxoid Conjugate Vaccine ; Meningococcal Polysaccharide Vaccine Menomune ; Menopur Menotropins Inj ; Menotropins Inj Menopur ; Mepergan Meperidine and Promethazine ; Meperidine and Promethazine Mepergan ; Mephyton Phytonadione ; Meprobamate Miltown ; Mepron Atovaquone ; Mercaptopurine Purinethol ; Meropenem Merrem I.V. ; Meruvax Rubella Virus Vaccine Live ; Mesalamine Lialda ; Mesalamine Rectal Suspension Enema Rowasa ; Mesnex Mesna ; Mestinon Pyridostigmine ; Metal4 Combination for Neonates ; Neotrace4 ; Metaraminol Aramine ; Metaxalone Skelaxin ; Metformin Hcl Glumetza ; Metformin hydrochloride Glucophage ; Methamphetamine Hydrochloride Desoxyn ; Methenamine Hippurate Hiprex ; Measles and Rubella Virus Vaccine Live MRVax ; Measles Virus Vaccine Live Attenuvax ; Mebaral Mephobarbital ; Mecamylamine Inversine ; Mecasermin Rinfabate [rDNA origin] Inj Iplex ; Meclizine Antivert ; Medrol Methylprednisolone ; Medroxyprogesterone Acetate DepoSubQ Provera ; Medrysone Hms ; Mefloquine Lariam ; Megace Megestrol acetate ; Megestrol acetate Megace ; Mellaril Thioridazine HCl ; Melphalan Alkeran ; Memantine HCL Namenda ; Menest Estrogens ; Menomune Meningococcal Polysaccharide Vaccine ; Menotropins Pergonal ; Mentax Butenafine ; Meperidine Demerol ; Mephobarbital Mebaral ; Mepivacaine Carbocaine ; Meprobamate and Aspirin Equagesic ; Mequinol & Tretinoin Solage ; Meridia Sibutramine Hydrochloride Monohydrate ; Merrem I.V. Meropenem ; Mesalamine Canasa ; Mesalamine CR Pentasa Cr ; Mesna Mesnex ; Mesoridazine Besylate Serentil ; Metadate Methylphenidate Hydrochloride ; Metaproterenol Sulfate Alupent ; Metastron Strontium89 ; Metformin Hcl Fortamet ; Metformin Hcl Riomet ; Methadone Dolophine ; Methazolamide Neptazane ; Methenamine Hippurate Urex and meperidine.

Tumor nance melphalan cells and medium harvested suspended neously amino tions Cells supplemented suspended melphalan nutrient-agar procedure Bone 20-25 ofChu marrow g were was were to acid in the of cell have eVtotoxicitt' of been of and growth lO desired melphalan, to an equivalent washed 20% medium by clonal 40 Fischer by sg ml with assays. cervical at LI2IO growth 0.25% 0.1 mM medium, cells mI. They the LDw volume twice l0 in cells mI. gentamicin minor. This Panel again shows Buttons which may or may not be there, according to the type of Object, curve or Surface. Top to bottom, left to right: Poly Bezier Curve only ; A polygon only gives a linear interpolation of vertices and mephenytoin. ICN Co, Ltd. Progress Med. Army Pharm M. March Osoth Dispensary Pharmasant Pharmasant Charoen Bhaesaj E. Merck Biolab E. Merck E. Merck AstraZeneca AstraZeneca AstraZeneca Rx. Co-Ph Pfizer Pfizer GPO L.B.S. Lab L.B.S. Lab The Forty Two Lab GPO Eli Lilly Aventis Pharma Aventis Pharma Siam Bhesaj Biolab L.B.S. Lab M&H.
A second set of autologous, GM-CSF-secreting melanoma vaccines. K030 received 11 immunizations with this material through February 1999, but the calf mass recurred and gradually became indurated. Although tissue could not be obtained, the lesion was assessed clinically as progressive tumor. The patient underwent isolated limb perfusion with tumor necrosis factorand melphalan followed by removal of a residual mass that showed extensive necrosis ; and radiation therapy. Two subsequent s.c. metastases were resected in November and December 1999, and both displayed extensive necrosis with lymphocyte infiltrates. Adenoviral-mediated gene transfer was used to manufacture a third batch of GM-CSF-secreting vaccines from this material. K030 received 18 more immunizations from March through September 2000, but she then developed a small bowel obstruction that required surgical intervention. In contrast to the previous lesions, pathologic examination of this metastasis disclosed the absence of tumor necrosis and the absence of tumorinfiltrating lymphocytes. A fourth round of vaccines was prepared from this sample, but after four immunizations, rapid disease progression ensued, and the patient died shortly thereafter in March 2001 and meprobamate. Chapter 3 Discussion The present study represents three patients with primary plasma cell leukemia PCL ; treated with highdose melphalan supported by PSC after induction therapy with VAD, highdose cyclophosphamide and EDAP courses. CR was attained in all cases. The decline in tumor load was most pronounced after VAD, indicating a very effective chemotherapy regimen for remission induction. Consolidation was further obtained with highdose cyclophosphamide, EDAP and HDM with peripheral stem cell support. Long term followup demonstrated two survivors, whereas one patient relapsed after 3 months. The optimal treatment for PCL is not well defined. A review of the literature Table 3.1 ; demonstrates that patients treated with a single agent with or without prednisone obtain CR in 026% of the cases and PR in about 13% of the cases. This includes in total 50 patients. Patients having a response to chemotherapy had a median survival of one year or more and less than one month for patients without a response. Combination therapy with VADlike regimens resulted in a higher response rate and a longer longterm survival in 66 patients studied. Patients treated according to this regimen demonstrated a CR in 6% and a PR in 42% range 3053% ; . These data suggest that intensive chemotherapy is most relevant for obtaining longterm survival.151, 173176 Autologous stem cell mobilization can easily be used in this patient group after remission induction with VAD, providing the opportunity for further dose intensification. Moreover, this approach provides the opportunity to select hematopoietic stem cells by CD34 selection or negative selection with monoclonal antibodies directed to the plasma cells, or a combination of both techniques. Alternatively allogeneic bone marrow transplantation may be used which has the advantage of the graftversusmyeloma effect.177 However, so far no distinct differences in survival have been seen with either approach.174 It was noticed that all patients developed oligoclonality posttransplantation. In one patient the oligoclonality had a transient character and disappeared 16 months posttransplantation, while the second patient developed progressive IgG paraprotein with different oligoclonal bands at relapse. The data suggest that the cause of the oligoclonality might vary between the different patients, an imbalance in the Bcell development posttransplantation or a dedifferentiation of the malignant Bcell clone. Tests can be used for prenatal diagnosis on amniotic fluid and or CVS. For questions regarding genetic testing, please call 800-345-GENE and mercaptopurine.

Luride + Lipitor ql qd . Liquid Pred 31, 38, 44 Lutropin Alpha . 31, 41 Lisinopril + 25-26 Luveris . 31, 41 Lisinopril Hydrochlorothiazide + Luvox ql + . Lithium Carbonate + Lyrica ql qd Tier 3, see therapeutic class 3.6 Lithium Carbonate, Sustained Action + Lysiplex Tier 3, see therapeutic class 15.1 Lithium Carbonate Tablet, Sustained Action + . 22 Lysodren . Lithium Citrate + Lithobid + Macrobid + Lithostat Tier 3, see therapeutic class 16.1 Macrodantin 25 mg Livostin Tier 3, see therapeutic class 12.15 Macrodantin 50, 100mg + . Ovral Tier 1 . Magan Tier 3, see therapeutic class 3.3.2 Lo Ovral + Tier 3 . Magsal Tier 3, see therapeutic class 3.1.2 Lobac Tier 3, see therapeutic class 3.3.2 Malarone Locholest Tier 3, see therapeutic class 4.6 Mandelamine Tier 3, see therapeutic class 1.7 Locholest Light Tier 3, see therapeutic class 4.6 Mantadil Tier 3, see therapeutic class 5.12 Locoid Maolate Tier 3, see therapeutic class 3.8.1 Lodine + 18, 38 Maprotiline HCl + Lodine XL + . 18, 38 Marax Tier 3, see therapeutic class 13.3.1 Lodoxamide TromethamineTier 3, see Marinol Tier 3, see therapeutic class 3.4.2, 8.3.4 therapeutic class 12.15 Marplan Tier 3, see therapeutic class 3.9.2.3 Loestrin Fe + . Matulane Loestrin + Mavik Tier 3, see therapeutic class 4.5.4 Lofibra . Maxair ql Tier 3, see therapeutic class 13.3.3 Lomotil + Maxair Autohaler ql Tier 3, see therapeutic class Lomustine 13.3.3 Loniten + Maxaquin ql Tier 3, see therapeutic class 1.5.1 Lopid + Maxalt ql qd . Lopressor + Maxalt MLT ql qd . Lopressor HCT + Maxitrol + Loprox 0.77% + . Maxivate 0.05% + . Lorabid Tier 3, see therapeutic class 1.3.4 Maxzide + Lorcet ql qd + May-Vita Elixir Tier 3, see therapeutic class 15.1 Lorcet Plus ql qd + Mebaral 32, 100mg + . Loratadine Tablet, Syrup OTC ; . Mebaral 50mg . Lorazepam + Mebendazole + Lortab ql qd + Mecasermin Tier 3, see therapeutic class 16.1 Lortab ASA Tier 3, see therapeutic class 3.1.2 Mecasermin Rinfabate PF qd Tier 3, see Losartan Potassium ql qd . therapeutic class 16.1 Losartan Potassium Meclizine HCl Tablet . 19, 36 Hydrochlorothiazide ql qd . Meclofenamate Sodium + 18, 38 Lotemax Tier 3, see therapeutic class 12.11 Meclomen + 18, 38 Lotensin + Medigesic Tier 3, see therapeutic class 3.1.2 Lotensin HCT + Medivert Tier 3, see therapeutic class 8.3.4 Loteprednol Tobramycin Medrol 2, 8, 16, 31, 38, 44 Lotrel ql Tier 3, see therapeutic class 4.5.8 Medrol 4mg + . 31, 38, 44 Lotronex ql qd N Tier 3, see therapeutic class Medroxyprogesterone Acet + 8.3.3 Medroxyprogesterone Acet ql + . Lotrisone + Medroxyprogesterone Acet ql Tier 3, see Lovastatin ql qd + therapeutic class 11.3.1 Lovastatin Sustained-Release Tablet ql qd . Medrysone . Lovenox ql Mefloquine HCl ql + . Loxapine HCl . Megace + Loxapine Succinate + Megestrol Acetate + Loxitane + Melanex Tier 3, see therapeutic class 5.12 Loxitane C Melfiat 104 Tier 3, see therapeutic class 16.3 Lozol + Mellaril + Lubiprostone Tier 3, see therapeutic class 8.3.3 Meloxicam ql + . 18, 38 Ludiomil + Melphalan Tablet . 11, 16 Lufyllin + Memantine ql Tier 3, see therapeutic class 5.5 Lufyllin GG + . Menest Tier 3, see therapeutic class 11.3.2 Lumigan ql Menopur Tier 3, #, see therapeutic class 7.4.2, Lunesta ql qd Tier 3 . Lupron 1mg 0.2ml + 16, 41 11.4.1 + Generic equivalent available. # Brand is in Tier 4 for members with a 4 Tier benefit. 61 and melphalan. Although there was no strict inter-patient correlation between the extent of the disease and the paraprotein level, most patients had a modest decrease in the paraprotein levels following treatment. Pre-transplant pulse dexamethasone induction may benefit patients who are too debilitated to undergo transplantation, although the possibility of rapid disease progression upon steroid taper is a concern. The toxicity of high-dose single agent melphalan with autologous stem cell and mesna. APPENDIX 3. Royal Decrees in relation to psychotropic substances PARAHEXYL hexyl-3 ttrahydro-7, 8, 9, 10 trimthyl-6, 6, 9 6H-dibenzo[b, d]pyranne ol-1 PMA p-mthoxy |ga-mthylphnthylamine PSILOCINE psilotsin ou [ dimethyl-amino ; -2 thyl]-3 indole-4-ol PSILOCYBINE; ROLICYCLIDINE PHP, PCPY STP DOM TENAMFETAMINE MDA TENOCYCLIDINE TCP TETRAHYDROCANNABINOL, les isomres suivants et leurs variantes strochimiques : - ttrahydro-7, 8, 9, 10 trimthyl-6, 6, 9 pentyl-3 6H-dibenzo[b, d]pyranne ol-1; - 9R, 10aR ; -ttrahydro-8, 9, 10, 10a trimthyl-6, 6, 9 pentyl-3 6H-dibenzo[b, d]pyranne ol-1; - 6aR, 9R, 10aR ; -ttrahydro-6a, 9, 10, 10a trimthyl-6, 6, 9 pentyl-3 6H-dibenzo[b, d]pyranne ol-1; - 6aR, 10aR ; -ttrahydro-6a, 7, 10, 10a trimthyl-6, 6, 9 pentyl-3 6H-dibenzo[b, d]pyranne ol-1; - ttrahydro-6a, 7, 8, 9 trimthyl-6, 6, 9 pentyl-3 6H-dibenzo[b, d]pyranne ol-1; - 6aR, 10aR ; -hexahydro-6a, 7, 8, 9, dimthyl-6, 6 mthylne-9 pentyl-3 6H-dibenzo[b, d]pyranne ol-1; TMA + ; -trimthoxy-3, 4, 5 |ga-mthylphnthylamine b ; AMFETAMINE; DELTA-9-TETRAHYDROCANNABINOL et ses variantes strochimiques 6aR, 10aR ; -ttrahydro-6a, 7, 8, 10a trimthyl-6, 6, 9 pentyl-3 6H-dibenzo[b, d]pyranne ol-1 DEXAMFETAMINE; FENETYLLINE; LEVAMFETAMINE; LEVOMETAMFETAMINE; MECLOQUALONE; METAMFETAMINE; METAMFETAMINE, RACEMATE DE; METHAQUALONE; METHYLPHENIDATE; PHENCYCLIDINE PCP PHENMETRAZINE; SECOBARBITAL; ZIPEPROL. 2. Ces dispositions sont aussi d'application aux : AMFEPRAMONE; BUFOTENINE hydroxy-5-dimethyltryptamine CLOBENZOREX; DIPROPYLTRYPTAMINE; ETILAMFETAMINE; FENPROPOREX; FURFENOREX; GHB acide gamma hydroxybutyrique IBOGAINE; KETAMINE; MBDB N-mthyl-1- benzodioxol-1, 3 yl-5 ; -2-butanamine MEFENOREX; PEYOTL; PIPRADROL; CHAMPIGNONS proprits hallucinognes, notamment des genres STROPHARIA, CONOCYBE et PSYLOCYBE. Art. 3. 1er. Nul ne peut importer, exporter, fabriquer, dtenir, vendre ou offrir en vente, dlivrer ou acqurir des substances psychotropes titre onreux ou titre gratuit, s'il n'en a obtenu l'autorisation gnrale pralable de Notre Ministre. Cette autorisation est personnelle et limite des fins scientifiques et mdicales. 2. Sans prjudice des dispositions des articles 18 et 20, les dispositions du 1er ne s'appliquent pas : 1 ; l'acquisition ou la dtention de mdicaments en vertu d'une prescription mdicale; 2 ; aux pharmaciens d'officine, aux pharmaciens tenant dpt dans un tablissement de soins ainsi qu'aux mdecins et mdecins-vtrinaires tenant dpt dans les limites des besoins de leur officine ou de leur dpt; 3 ; aux mdecins et mdecins-vtrinaires ne tenant pas dpt et aux praticiens de l'art dentaire, dans les limites de leurs besoins professionnels conformment aux lois et rglements. Art. 4. 1er. La demande de l'autorisation gnrale vise l'article 3, 1er est envoye au Service des stupfiants par lettre recommande la poste. Elle comprend les renseignements suivants.